v The primary objective of the Tetramer Core is to produce Class I MHC-peptide tetramers for use by the investigators in this Program Project. This technology, pioneered in the laboratories of Davis and McMichael, is now established as a highly useful approach in studies of cell mediated immune responses to pathogens. This core facility will directly support Projects 1, 2 and 3. Class I MHC-peptide tetramers will be used to detect and sort virus-specific CD8+ T cells. With these reagents, CD8+ T cells that are specific for Epstein Barr virus (EBV), Cytomegalovirus, Influenza virus, Yellow Fever virus, and Vaccinia virus can be quantified and characterized in clinical specimens and experimental systems. This core facility will provide cost-effective, high quality reagents to investigators. We will prioritize production based on considerations including MHC Class I allele frequencies in study populations, and the identification of novel optimal peptide epitopes and their restricting elements. The experience that has been accrued by this laboratory in the production of reagents over the past seven years will allow us to extend production to additional Class I MHC alleles, and to easily include different peptide epitopes as required by Program Project investigators. This core facility has a proven track record of tight quality control, and the timely production of Class I MHC- peptide tetramers greatly enhancing the ability of Program Project investigators to isolate, enumerate and characterize virus-specific CD8+ T cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI049320-08
Application #
7631358
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
8
Fiscal Year
2008
Total Cost
$228,045
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Weiss, Eric R; Lamers, Susanna L; Henderson, Jennifer L et al. (2018) Early Epstein-Barr Virus Genomic Diversity and Convergence toward the B95.8 Genome in Primary Infection. J Virol 92:
Song, InYoung; Gil, Anna; Mishra, Rabinarayan et al. (2017) Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope. Nat Struct Mol Biol 24:395-406
Watkin, Levi B; Mishra, Rabinarayan; Gil, Anna et al. (2017) Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion. J Allergy Clin Immunol 140:1206-1210
Weiss, Eric R; Alter, Galit; Ogembo, Javier Gordon et al. (2017) High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis. J Virol 91:
Aslan, Nuray; Watkin, Levi B; Gil, Anna et al. (2017) Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires. MBio 8:
Gil, Anna; Yassai, Maryam B; Naumov, Yuri N et al. (2015) Narrowing of human influenza A virus-specific T cell receptor ? and ? repertoires with increasing age. J Virol 89:4102-16
Gil, Anna; Kenney, Laurie L; Mishra, Rabinarayan et al. (2015) Vaccination and heterologous immunity: educating the immune system. Trans R Soc Trop Med Hyg 109:62-9
Greenough, Thomas C; Straubhaar, Juerg R; Kamga, Larisa et al. (2015) A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection. J Immunol 195:4185-97
Renzette, Nicholas; Somasundaran, Mohan; Brewster, Frank et al. (2014) Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids. J Virol 88:3744-55
Chen, Alex T; Cornberg, Markus; Gras, Stephanie et al. (2012) Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog 8:e1002633

Showing the most recent 10 out of 38 publications